Utah Retirement Systems acquired a new stake in shares of Patheon NV (NASDAQ:PTHN) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 6,100 shares of the company’s stock, valued at approximately $212,000.

A number of other hedge funds also recently modified their holdings of the business. Wellington Management Group LLP raised its position in Patheon NV by 66.5% during the first quarter. Wellington Management Group LLP now owns 4,604,034 shares of the company’s stock valued at $121,270,000 after purchasing an additional 1,839,609 shares during the period. JPMorgan Chase & Co. raised its position in Patheon NV by 5.1% during the first quarter. JPMorgan Chase & Co. now owns 3,676,853 shares of the company’s stock valued at $96,848,000 after purchasing an additional 178,619 shares during the period. Schroder Investment Management Group raised its position in Patheon NV by 68.3% during the first quarter. Schroder Investment Management Group now owns 1,007,821 shares of the company’s stock valued at $26,375,000 after purchasing an additional 409,100 shares during the period. OppenheimerFunds Inc. purchased a new stake in Patheon NV during the first quarter valued at approximately $24,290,000. Finally, Redmile Group LLC raised its position in Patheon NV by 87.6% during the first quarter. Redmile Group LLC now owns 826,843 shares of the company’s stock valued at $21,779,000 after purchasing an additional 386,123 shares during the period.

TRADEMARK VIOLATION NOTICE: “Utah Retirement Systems Acquires New Stake in Patheon NV (PTHN)” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://www.thecerbatgem.com/2017/09/17/utah-retirement-systems-acquires-new-stake-in-patheon-nv-pthn.html.

Patheon NV (PTHN) opened at 34.98 on Friday. The company has a market cap of $5.08 billion and a PE ratio of 44.85. The stock’s 50 day moving average price is $34.98 and its 200-day moving average price is $33.37. Patheon NV has a 1-year low of $24.45 and a 1-year high of $35.02.

PTHN has been the topic of a number of recent research reports. Raymond James Financial, Inc. downgraded Patheon NV from an “outperform” rating to a “mkt perform” rating in a research report on Friday, June 9th. Zacks Investment Research upgraded Patheon NV from a “hold” rating to a “buy” rating and set a $39.00 price objective on the stock in a research report on Saturday, June 10th. J P Morgan Chase & Co downgraded Patheon NV from an “overweight” rating to a “neutral” rating in a research report on Thursday, June 8th. Jefferies Group LLC restated a “hold” rating and set a $35.00 price objective on shares of Patheon NV in a research report on Friday, July 21st. Finally, BidaskClub downgraded Patheon NV from a “sell” rating to a “strong sell” rating in a research report on Saturday, September 2nd. One analyst has rated the stock with a sell rating, seven have given a hold rating and one has assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $34.50.

Patheon NV Company Profile

Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company’s segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products.

Institutional Ownership by Quarter for Patheon NV (NASDAQ:PTHN)

Receive News & Stock Ratings for Patheon NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Patheon NV and related stocks with our FREE daily email newsletter.